[Form 4/A] Standard BioTools Inc. Amended Insider Trading Activity

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) – Form 4/A (filed 07/30/25)

Director Troy Cox filed an amended Form 4 to correct the share count shown in Column 5 of Table I of the original filing dated 06/24/25. After the correction, Cox is shown as beneficially owning 319,322 shares of LAB common stock. No new acquisitions, dispositions, option exercises, or derivative positions are reported; the filing strictly updates the post-transaction ownership figure. All other data from the original Form 4 remain unchanged. Because the amendment merely revises record-keeping and does not reflect a new transaction, the disclosure is administrative in nature and has negligible economic impact on shareholder value or float.

Insights

Securities Analyst

TL;DR: Administrative correction; no buying or selling, neutral impact.

This Form 4/A only adjusts Director Troy Cox’s reported holdings to 319,322 LAB shares as of 06/20/25. There is no fresh insider buying or selling signal, nor any change in derivative exposure. Such clean-up filings are routine after clerical errors and carry minimal information value for price discovery. Investors may simply note Cox’s updated stake size for ownership models but should not infer sentiment or liquidity effects.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cox Troy

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

2 TOWER PLACE, STE 2000

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/24/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								319,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4/A is being filed solely to correct the number of securities beneficially owned by the Reporting Person as of June 20, 2025 that was reported in Column 5 in Table I of the Form 4 filed June 24, 2025 (the "Original Form 4"). All other information reported in the Original Form 4 remains the same.

	/s/ Troy Cox by Tomone Tanaka, Attorney-in-Fact	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Standard BioTools (LAB) file this amended Form 4/A?

The amendment corrects the number of shares Director Troy Cox beneficially owned as of 06/20/25, replacing an incorrect figure in the original 06/24/25 filing.

How many LAB shares does Director Troy Cox now report owning?

The corrected filing shows 319,322 shares of common stock held directly.

Does the Form 4/A indicate any recent purchase or sale by Troy Cox?

No. It reports no new transactions; it only updates the post-transaction ownership number.

Is there any change to derivative securities in this amendment?

No derivative positions are listed, and no changes to options or warrants are disclosed.

What is the filing date of this Form 4/A?

The amended Form 4 was filed on 07/30/2025.